ABSTRACT. The purpose of this study was to investigate the pathology of zymosan-induced arthritis in the SKG mouse model of rheumatoid arthritis in humans, and to validate this model as a reliable drug screening system. To achieve this purpose, methotrexate (1 or 10 mg/kg, once daily) or vehicle only was administered intraperitoneally to SKG mice with zymosan-induced arthritis. Histologically, this arthritis was characterized by the presence of granulation tissue rich in granulocytes. Methotrexate suppressed the development of arthritis in ankle and wrist joints in both clinical and histological studies. These results indicated that methotrexate has not only prophylactic, but also therapeutic effects on zymosan-induced arthritis developed in SKG mice and may thus be a promising control agent for drug research in the SKG mouse model of rheumatoid arthritis.
Rheumatoid arthritis (RA) is characterized by chronic inflammation of the synovial joints leading to progressive destruction of the cartilage and bone [2] . Work disability is seen in 60% of RA patients 10 years after onset of this disease, and mortality is increased in patients with severe RA [13] . The discovery of RA drugs has benefited greatly from animal models, such as adjuvant-induced arthritis in rats, collagen-induced arthritis in rats and mice and streptococcal cell wall-induced arthritis in rats [7, 16] ; these models have all made contributions to the RA drugs used today [1, 3, 12, 14] . However, several differences exist between such models and the actual disease state of RA in humans that may limit their effectiveness in screening promising new drugs. Notably, classic animal models show a lack of cartilage damage and vary in terms of the type of immune cells infiltrating lesions [16] . Therefore, a new model bearing closer pathology to the actual human disease is desirable for discovery of more efficient drugs for treatment of RA.
Histologically, the diseased joints of SKG mice have been found to express human RA-like features, including subsynovial infiltration of inflammatory cells and plasma cells and synovial cell proliferation with pannus formation and neovascularization. SKG mice are derived from a closed breeding colony of BALB/c mice and show the phenotype of spontaneous chronic arthritis development. Sakaguchi et al. detected a mutation in the ZAP-70 gene in SKG mice that was found to be the cause of autoimmune T cell tolerance by altering lymphocyte selection in the thymus [15] . Moreover, it has been reported that intraperitoneal injection of -1,3-D-glucans (-glucan), such as laminarin or zymosan, could successfully induce the onset of the arthritis in SKG mice, which is thought to increase the efficiency of this model as a screening tool [8, 17] .
The aim of this study was to evaluate the SKG mouse model in terms of establishing a more accurate screening system for RA drug development. Methotrexate (MTX), the standard for disease-modifying anti-rheumatic drugs in humans, was chosen as a reference agent to assess its pharmacological effects in the SKG model as well as to serve as a control reagent for the SKG mouse system in future drug screening using this mouse line.
MATERIALS AND METHODS

Animals:
Thirty female SKG mice (SKG/Jcl; 7 wks old) were purchased from CLEA Japan, Inc. (Tokyo, Japan). After a quarantine/acclimatization period, the mice were separated into groups by repeated stratified randomization using their latest measured body weights. The mice were housed in flat-bottom cages and had free access to water and food throughout the study. All animal in-life procedures were approved by the Institutional Animal Care and Use Committee of the Division of Laboratory Animal Research of Shinshu University.
In-life study: Zymosan (Sigma Aldrich Japan K.K., Tokyo, Japan) was dissolved in sterile saline to up to 4 mg/ ml and warmed in hot water for 10 min. Mice were intraperitoneally injected with 0.5 ml of the solution to up to 2 mg of Zymosan each on Day 0. The study consisted of the following six groups ( Fig. 1 ): intact (Group 1; not receiving Zymosan; n=5), vehicle (Group 2; n=5), MTX 1 mg/kg prophylactic regimen (Group 3; n=5), MTX 10 mg/kg prophylactic regimen (Group 4; n=5), MTX 1 mg/kg therapeutic regimen (Group 5; n=5) and MTX 10 mg/kg therapeutic regimen (Group 6; n=5). Dosages were determined according to previous reports [9, 11] . MTX (Wako Pure Chemical Industries, Ltd., Osaka, Japan) was first dissolved in 1 N NaOH, and diluted with phosphate-buffered saline to the appropriate concentration and then sterilized by filtration. Groups 3 and 4 and Groups 5 and 6 were treated daily by intraperitoneal injection beginning on Day 1 and Day 20, respectively.
Clinical scoring: All parameters were measured in a blinded manner to avoid data bias. Clinical scores for limbs were recorded in accordance with criteria described previously [15] . Joint swelling was monitored by inspection and scored as follows: 0, no joint swelling; 0.1, swelling of one finger joint; 0.5, mild swelling of wrist or ankle; and 1.0, severe swelling of wrist or ankle. The scores for all fingers of forepaws and hind paws, wrists, and ankles were then totaled for each mouse.
Histopathological investigations: All mice were euthanized on Day 30 for histopathological investigations. The left tarsal joints of all animals were fixed in 10% phosphatebuffered formalin. After decalcification using K-CX solution (Falma, Tokyo, Japan), the tissues were embedded in paraffin, cut into sections 3-m thick and stained with hematoxylin and eosin (H&E). The H&E-stained preparations were microscopically observed focusing on the distal tibia-talocrural joint. The scoring methods were based on previous reports [10] . Briefly, the sum of a 4-point scoring system (0, no significant changes, 1, mild, 2, moderate, 3, marked) was considered as the histopathological score of each section, and the average score of each group was compared for bone erosion, new bone formation, pannus formation, cartilage destruction, synovial cell hyperplasia, inflammatory cell infiltration, circumarticular fibrosis and edema.
Immunohistochemical examinations: Immunohistochemistry for inflammatory cell types was carried out on serial talocrural joint sections using the primary antibodies shown in Table 1 in accordance with the manufacturers' instructions. Histofine Simple Stain Mouse MAX PO (Rat; Nichirei Corporation, Tokyo, Japan) was used as the secondary antibody in all cases except for anti-CD3 (M-20), which was visualized with Histofine Simple Stain Mouse MAX PO (Goat; Nichirei Corporation, Tokyo, Japan). Counterstaining was performed with hematoxylin. Immunohistochemical scoring was conducted using a 5-point scoring system (-, , +, ++ and +++). For the inflammatory cell population analysis, each cell type was counted using  400 magnification, corresponding to an optical field of 0.185 mm 2 . Three fields were chosen among the same anatomical locations within the preparations, which were the dorsum of the foot, plantar side of the calcaneus and tibial side of the calcaneus.
Statistics: Statistical analysis of clinical scores was carried out by one-way analysis of variance followed by Scheffe's Method.
RESULTS
MTX treats arthritis in SKG mice both prophylactically and therapeutically: Group 2 mice sensitized with zymosan developed symptoms of arthritis as described previously [9] , but the non-sensitized Group 1 animals were unaffected (Fig. 1) . Development of the disease occurred almost simultaneously among the mice not treated with MTX on day 11. In the Group 3 and 4 mice following the prophylactic regimen, MTX suppressed the development of the disease and virtually prevented all symptoms in Group 4. MTX also showed marked therapeutic effects on the existing arthritis (Table 2) . Bone erosion, new bone formation, pannus formation, articular cartilage destruction, stratification or cystic hyperplasia of synovial cells, inflammatory cell infiltration, circumarticular fibrosis and edema were all found in Group 2 (Fig. 2B ), but not in Group 1 ( Fig. 2A) . Group 2 mice also showed signs of extreme inflammation, including inflammatory cell infiltration and bone erosion (Fig. 2B1) . Interestingly, new bone formation and cartilage destruction were rather mild. The mice in Group 4 showed marked reductions in all symptomatic findings compared with Group 2, while Group 3 mice expressed intermediate scores between the two. Mice treated therapeutically expressed very similar results (Fig.  2C) ; the clinical scores of Group 6 were notably ameliorated.
Inflammatory cell subpopulation analysis: To understand the features of inflammation in SKG mice compared with the pathology of RA in humans, tissue sections were investigated by immunohistochemical staining of inflammatory cell subpopulations. The granulocyte marker Ly-6G/Ly-6C, B-cell marker CD45R/B220 and T-cell marker CD3 were all positive in the inflammatory lesions induced by zymosan sensitization (Table 3 and Fig. 3 ). CD34-positive endothelial cells were also detected in these lesions, indicating development of granulation tissue at the inflammation site. However, two monocyte/macrophage-specific markers, Mac-3 and F4/80, did not react to the zymosan-induced lesions, suggesting the absence of monocytes and macrophages at the inflammation site. Inflammatory cells positive for these markers were rarely found in intact mice or MTXtreated SKG mice. Additionally, the numbers of each cell type were counted, and granulocytes were the major cell type detected at the site of inflammation (Fig. 4) .
DISCUSSION
In the present study, the pathology of zymosan-induced arthritis in SKG mice was evaluated. MTX showed clear effects in both clinical and histological tests. Control SKG mice did not develop any spontaneous inflammatory lesions throughout the trial, while mice receiving zymosan showed clear and synchronized induction of arthritis, indicating that the zymosan-induced SKG mouse model can indeed be a valuable drug screening system. Zymosan, a cell wall component of Saccharomyces cerevisiae, is a crude extract that contains carbohydrate components, such as -glucan, which are also found in other fungi, including Candida albicans and Laminaria digitata. These components are believed to be responsible for innate immune induction via production of prostanoids, activation of the complement system and direct activation of immune cells via the -glucan receptor Dectin-1 [4, 5, 8, 18] . However, arthritis deemed to be due to this immune system activation is not observed in wild type BALB/c mice after systemic injection of -glucans, which results in insufficient induction of arthritis [17] . Collectively, these reports suggest the involvement of both genetic and environmental factors in the pathogenesis of arthritis in SKG mice, which is also the case in human RA.
The lesions found in our experiment were located mainly in ankles and wrists, but not in finger joints. This is a slight discrepancy from other literature that has reported swelling in the finger joints as well in spontaneous arthritis in SKG mice [15] . Our findings are also unlike collagen-induced arthritis, which first affects digits in the hind and fore paws before spreading to multiple sites in the paw [6] . Immunohistochemical examinations revealed severe granulocyte infiltration to be the dominant feature of SKG mice lesions, with T and B cell infiltration occuring to a lesser extent. Granulation tissue was typically observed to contain endothelial cells at the inflammation site; however, macrophages and monocytes were rarely seen. In addition, the histological sections from the mice with zymosan-induced arthritis suggested that the nature of the disease was one of acute rather than chronic inflammation as compared with the spontaneous lesions seen in earlier SKG mouse literature.
In clinical examinations, MTX efficiently suppressed disease development when dosed prophylactically and improved disease symptoms when given in a therapeutic regimen. Disease suppression was seen both in clinical parameters and histological findings across the whole pathology of arthritis. One of the proposed targets of MTX immune suppression is T cells [10] . As the pathology of SKG mice is dependent on autoreactive T cells presumably by genetic alteration [15] , it is reasonable to hypothesize Marked bone erosion and synovial cell hyperplasia can be seen in B, and severe inflammatory cell infiltration can be seen in B1 for the mice in Group 2 (boxed area in B is enlarged as B1). C. No abnormal findings were observed for the mice in Group 6 (boxed area in C is enlarged as C1). H&E stain. The scale bar for A, B and C is 1 mm and that for A1, B1 and C1 is 100 m. that the MTX mechanism of action in this model is directly mediated by its effect on the irregular T cells circulating in SKG mice. In summary, we conclude that the SKG mouse model of RA faithfully reproduced the clinical disease-modifying performance of MTX. Thus, we suggest that these mice will not only provide another in vivo drug screening system for RA drug discovery, but also that MTX itself may become a comparative control agent for future pharmacological studies targeting T cells.
